Abstract: Synthesis of a compound 3,5-dinitro-N-(pyrimidin-2-ylcarbamothioyl)benzamide and its use as an insecticidal agent.

Abstract: Provided are a novel boron-containing compound and an electrolyte solution additive for a secondary battery including the same. The electrolyte solution for a secondary battery provided in one embodiment includes the novel boron-containing compound, thereby suppressing the decomposition of an electrolyte solution to improve the capacity and the life characteristics of a battery.

Abstract: This invention relates to a process for producing cyanoacetates involving contacting a salt of an alkyl, alkenyl, alkynyl or aryl formyl acetate with a hydroxyl amine acid under appropriate conditions and for a time sufficient to yield a cyanoacetate.

Abstract: Synthesis of a compound 3,5-dinitro-N-(pyrimidin-2-ylcarbamothioyl)benzamide and its use as an insecticidal agent.

Abstract: A N?-(2-naphthoyloxy)-2-(benzo[d]oxazol-2-yl)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: A 2-(benzo[d]oxazol-2-yl)-N?-(3,5-dichlorobenzoyloxy)acetimidamide compound, its synthesis, and its use as an antimicrobial agent.

Abstract: Reanalysis of the SIMPLIFY 1 and 2 trials data indicates MMB is effective in JAKi-naïve patients and in second line therapy to RUX, providing benefits of reducing enlarged spleens, improving myelofibrosis-related symptoms, and increasing transfusion independence in patient at risk for thrombocytopenia from the underlying disease and RUX therapy. Accordingly, methods of treating myeloproliferative neoplasms (MPN) such as myelofibrosis are described. The methods can include administering a therapeutically effective amount of momelotinib or a pharmaceutically acceptable salt thereof to a subject identified as having (i) myelofibrosis and (ii) a platelet count of less than 150×109/L.

Abstract: Disclosed herein are novel cycloalka[b]heteroaryl compounds having CX3CR1/fractalkine receptor (CX3CR1) agonistic properties, pharmaceutical compositions comprising these compounds, chemical processes for preparing these compounds and their use in the treatment or prophylaxis of diseases associated with CX3CR1 receptor activity in animals, in particular humans.

Abstract: Provided is a compound superior in an ATX inhibitory action and useful for the prophylaxis or treatment of diseases involving ATX. A carboxylic acid compound represented by the following formula (1) or a pharmacologically acceptable salt thereof: wherein each symbol is as defined in the SPECIFICATION.

Abstract: Provided herein are compounds useful in the treatment of inflammatory diseases, pharmaceutical compositions comprising the same, and methods of use and preparation thereof. The compounds exhibit inhibitory effects on the expression and secretion of pro-inflammatory cytokines, such as IL-1?, IL-6 and TNF-?.

Abstract: The present invention is directed to compounds of formulae (I) and (II) wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.

Abstract: The present disclosure includes compositions and methods for improved DNA amplification reactions. In particular, the present disclosure provides compositions and methods for hot-start PCR applications using DNA polymerase inhibitors that minimize non-specific DNA amplification by inactivating DNA polymerase at lower temperatures.

Abstract: Methods and compounds are disclosed for treating a disease or condition by inhibiting PSMA (Prostate Specific Membrane Antigen) using prodrugs of 2-PMPA.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: Crystalline forms of ACP-196, preparation methods, pharmaceutical compositions and uses thereof in the preparation of drugs for treatment and/or prevention of Bruton's tyrosine kinase (BTK)-mediated disorders such as autoimmune diseases or disorders, heteroimmune diseases or disorders, cancers including lymphoma and inflammatory diseases or disorders. As compared with the known solid form of ACP-196, the crystalline forms of the present invention have advantages in crystallinity.

Abstract: The present invention provides a compound that have excellent harmful arthropod controlling effects, the compounds being represented by formula (I) [wherein R1 represents a hydrogen atom etc., and R21, R22, R31 and R32 are identical to or different from each other and each represents a hydrogen atom etc., Q1, Q2, Q3, Q4 are identical to or different from each other and each represents CH etc.], as well as a composition comprising the same, and a method for controlling harmful arthropod comprising applying the same.

Abstract: A structural modification of vitamin C designed to increase its antioxidant activity is provided. The approach involves the substitution of the hydroxyl group (OH) by fluorine (F) at position 4 of vitamin C, resulting in the formation of a new structure. Based on quantum calculations, this modification may enhance the antioxidant properties of vitamin C and its ability to scavenge free radicals.

Abstract: The present application relates to a 2,3-dihydro-1H-pyrrolizine-7-formamide derivative as a nucleoprotein inhibitor and a use in preparation of a drug for treating HBV related diseases. The present application specifically relates to a compound represented by formula (II), and isomers or pharmaceutically acceptable salts thereof.

Abstract: The present disclosure relates to indole compounds and pharmaceutical compositions thereof, and their use in stimulating the immune system of patients in need thereof and in treating cancer.